Introduction This report examines the opportunities presented to the developers of molecular diagnostics by the emergence of novel/variant pathogens and ways in which new molecular testing technologies are being translated into superior diagnostic products in areas such as healthcare-associated infections; HPV infections, blood-borne viral infections and respiratory viral infections. Features and benefits Understand the nature and limitations of traditional molecular diagnostics and the improved features of molecular testing technologies in development.
Evaluate the competitive landscape in infectious disease molecular diagnostics and identify potential licensing/collaborative partners.
Analyze the factors stimulating increased demand for molecular testing in specific infectious disease areas to inform investment decisions.
Gain an insight into new and untapped opportunities revealed by recent research findings in the more mature sectors of the MDx market.
Identify key trends in the MDx market and plan future developments with the aid of market forecasts for the individual segments of the market. Highlights The latest molecular diagnostics to enter development are multiplex tests which can identify several pathogens or variants of these pathogens present in small-volume samples. Low- and medium-density bead-based microarrays are being developed and are expected to play an increasingly important role in multiplex pathogen detection and genotyping. It is likely that future diagnostic tests will target many more pathogens than is currently the case. Promising approaches include miniaturized microfluidic systems, in particular continuous-flow droplet-based PCR systems, and mass spectrometry-based detection methods which use direct specimen testing and virtually no reagents. Growth forecasts are derived for key MDx market segments for the period 2010-2015: the HPV testing market is forecast to grow with a 5-year CAGR of 20%, the hospital-associated infection (HAI) testing market is forecast to grow with a 5-year CAGR of 19%. and the virology (HIV/HCV/HBV) testing market is forecast to grow with a 5-year CAGR of 8%. Your key questions answered Which are the areas of unmet need in infectious disease testing and potential new areas of opportunity for MDx in infectious disease?
What forces are shaping molecular diagnostic testing trends and what drivers and restraints operate in the infectious disease testing market?
Who is developing new innovative products for the infectious disease MDx market and what paths to commercialization are they following?
How are the different sectors of the infectious disease MDx market forecast to develop and what are the prospects for new market entrants?
What are the estimated current market sizes and 5-year growth forecasts for the expanding sectors of the infectious disease MDx market? Contain 168 pages and 30 tables/figures.
|